Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

NCT00347555 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

NIH

Sponsor class

Conditions

Plasmodium Falciparum Malaria

Interventions

BIOLOGICAL: Aluminum Phosphate
DRUG: Placebo
BIOLOGICAL: EBA-175 RII-NG Malaria Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)